@RossFirestone
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Physician scientist @MSKCancerCenter via @DOMSinaiNYC @einstein_mstp
Joined April 2023
- Tweets27
- Following167
- Followers237
- Likes163
Ross Firestone retweeted
Together with @RossFirestone and @szusmani
we are happy to share our thoughts on SUCCESSOR-2 clinical trial published few days ago on @TheLancet
#mmsm #mezigdomide @MSKCancerCenter @MSK_DeptOfMed thelancet.com/journals/lance…
Ross Firestone retweeted
#Myeloma Paper of the Day: A differentiated T-cell repertoire (CD8+CD45RA+CD62L-CCR7- T effector cells re-expressing CD45RA (TEMRA)) may define a functionally high-risk group (median time to progression of 2.1 years) of smoldering myeloma patients: pubmed.ncbi.nlm.nih.gov/4206…. #mmsm
Ross Firestone retweeted
Myeloma Paper of the Day, August 26th, Suggested by Robert Orlowski (@Myeloma_Doc)
@RossFirestone @DrOlaLandgren @szusmani @LesokhinMD
oncodaily.com/science/myelom…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma @CancerWorldmag
Ross Firestone retweeted
#Myeloma Paper of the Day: Immune-MRD status informs tumor-MRD outcome prognostication in myeloma pts on Len maintenance; T cell profiles enriched w/ activated cytotoxic effectors predict early relapse & quiescent/naïve T-cells predicting remission: pubmed.ncbi.nlm.nih.gov/4085…. #mmsm
Ross Firestone retweeted
It was fun to work with @RossFirestone in writing this editorial for @BloodPortfolio #Blood "More than myeloma: the trouble with “normal” plasma cells", on the recent article from @nickbolli @matteoclaudio84 sciencedirect.com/science/ar… @MSKCancerCenter @MSK_DeptOfMed #mmsm
Ross Firestone retweeted
1/ 🚨New research alert! 🚨Our study in @BloodCancerJnl shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma (MM), with @RossFirestone, @MalinHultcrantz, @LarryNortonMD, @szusmani, and the rest of the @MSKCancerCenter team! 🧵👇
Ross Firestone retweeted
Therapy–mediated BCMA expression loss after belantamab or anti-BCMA chimeric antigen receptor T cells underlies teclistamab failure in RRMM. ow.ly/sarP50SM9ys #lymphoidneoplasia #immunobiologyandimmunotherapy #multiplemyeloma
Our work with @szusmani and @DavidJChungMD at @MSKCancerCenter looking at antigen escape with BCMA-targeting therapies in #MMSM patients is now out in @BloodJournal authors.elsevier.com/a/1jUXn… 1/7
We also found that, at times of active disease, low or undetectable levels of soluble BCMA reported on expression loss, offering a noninvasive method to test BCMA expression in clinical practice settings 6/7
Conclusion: We need to do a better job preparing patients for the expected complications of BsAb and CAR T therapies (both major and minor) to avoid unnecessary healthcare interactions and improve QoL, while still keeping patients safe. 5/6
We also can't ignore that remote healthcare utilization is part of the patient experience. Portal messages and phone calls, while not as burdensome as in-person visits, are important signals of patient unease. #rUHI 6/6
In this study we looked at unscheduled healthcare interactions in MM patients receiving CAR T or BsAbs, with a focus on remote interactions. We found that healthcare utilization was high, even in patients responding well to treatment. 2/6
Remote and in-person healthcare utilization was higher in BsAb patients, seemingly due to an increased incidence of low-risk infections (URIs, etc). 3/6
Excited to see our manuscript on healthcare utilization in CAR T and bispecifics patients with #MMSM in press! This work was spearheaded by Anna Howard RN and @isabelconcepci MSN FNP-C. ashpublications.org/bloodadv… 1/6
